Glucose-6-phosphatase inhibitors for the treatment of Type 2 diabetes

ISSN： 1354-3776

Source： Expert Opinion on Therapeutic Patents, Vol.11, Iss.9, 2001-09, pp. : 1429-1441

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Emerging sodium/glucose co-transporter 2 inhibitors for type 2 diabetes

By Boyle Luke D Wilding John PH

Expert Opinion on Emerging Drugs, Vol. 18, Iss. 3, 2013-09 ,pp. : 375-391

Informa Healthcare

Access to resources Recommend Favorite

Discovery of 6-Deoxydapagliflozin as a Highly Potent Sodium-dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Medicinal Chemistry, Vol. 10, Iss. 3, 2014-05 ,pp. : 304-317

Bentham Science Publishers

Access to resources Recommend Favorite

Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes

By Drucker DJ

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 1, 2003-01 ,pp. : 87-100

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic potential of ACE inhibitors for the treatment of hypertension in Type 2 diabetes

By Komers R. Komersova K.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2601-2617

Informa Healthcare

Access to resources Recommend Favorite

Glycogen phosphorylase inhibitors for treatment of type 2 diabetes mellitus

By Treadway J.L. Mendys P. Hoover D.J.

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 3, 2001-03 ,pp. : 439-454

Informa Healthcare

Access to resources Recommend Favorite